Literature DB >> 17079677

Ataxin-3 represses transcription via chromatin binding, interaction with histone deacetylase 3, and histone deacetylation.

Bernd O Evert1, Julieta Araujo, Ana M Vieira-Saecker, Rob A I de Vos, Sigrid Harendza, Thomas Klockgether, Ullrich Wüllner.   

Abstract

Ataxin-3 (AT3), the disease protein in spinocerebellar ataxia type 3 (SCA3), has been associated with the ubiquitin-proteasome system and transcriptional regulation. Here we report that normal AT3 binds to target DNA sequences in specific chromatin regions of the matrix metalloproteinase-2 (MMP-2) gene promoter and represses transcription by recruitment of the histone deacetylase 3 (HDAC3), the nuclear receptor corepressor (NCoR), and deacetylation of histones bound to the promoter. Both normal and expanded AT3 physiologically interacted with HDAC3 and NCoR in a SCA3 cell model and human pons tissue; however, normal AT3-containing protein complexes showed increased histone deacetylase activity, whereas expanded AT3-containing complexes had reduced deacetylase activity. Consistently, histone analyses revealed an increased acetylation of total histone H3 in expanded AT3-expressing cells and human SCA3 pons. Expanded AT3 lost the repressor function and displayed altered DNA/chromatin binding that was not associated with recruitment of HDAC3, NCoR, and deacetylation of the promoter, allowing aberrant MMP-2 transcription via the transcription factor GATA-2. For transcriptional repression normal AT3 cooperates with HDAC3 and requires its intact ubiquitin-interacting motifs (UIMs), whereas aberrant transcriptional activation by expanded AT3 is independent of the UIMs but requires the catalytic cysteine of the ubiquitin protease domain. These findings demonstrate that normal AT3 binds target promoter regions and represses transcription of a GATA-2-dependent target gene via formation of histone-deacetylating repressor complexes requiring its UIM-associated function. Expanded AT3 aberrantly activates transcription via its catalytic site and loses the ability to form deacetylating repressor complexes on target chromatin regions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17079677      PMCID: PMC6674535          DOI: 10.1523/JNEUROSCI.2053-06.2006

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  60 in total

Review 1.  Toward understanding Machado-Joseph disease.

Authors:  Maria do Carmo Costa; Henry L Paulson
Journal:  Prog Neurobiol       Date:  2011-11-23       Impact factor: 11.685

Review 2.  Epigenetics in nucleotide repeat expansion disorders.

Authors:  Fang He; Peter K Todd
Journal:  Semin Neurol       Date:  2012-01-21       Impact factor: 3.420

3.  The de-ubiquitinating enzyme ataxin-3 does not modulate disease progression in a knock-in mouse model of Huntington disease.

Authors:  Li Zeng; Sara J Tallaksen-Greene; Bo Wang; Roger L Albin; Henry L Paulson
Journal:  J Huntingtons Dis       Date:  2013

4.  Divalproex sodium modulates nuclear localization of ataxin-3 and prevents cellular toxicity caused by expanded ataxin-3.

Authors:  Zi-Jian Wang; Aoife Hanet; Daniel Weishäupl; Inês M Martins; Anna S Sowa; Olaf Riess; Thorsten Schmidt
Journal:  CNS Neurosci Ther       Date:  2018-01-09       Impact factor: 5.243

Review 5.  An update on inherited ataxias.

Authors:  Tanja Schmitz-Hübsch; Thomas Klockgether
Journal:  Curr Neurol Neurosci Rep       Date:  2008-07       Impact factor: 5.081

6.  Ataxin-3 expression correlates with the clinicopathologic features of gastric cancer.

Authors:  Li-Xia Zeng; Yong Tang; Yun Ma
Journal:  Int J Clin Exp Med       Date:  2014-04-15

7.  PolyQ-expanded ataxin-3 interacts with full-length ataxin-3 in a polyQ length-dependent manner.

Authors:  Na-Li Jia; Er-Kang Fei; Zheng Ying; Hong-Feng Wang; Guang-Hui Wang
Journal:  Neurosci Bull       Date:  2008-08       Impact factor: 5.203

8.  Physiological and pathophysiological characteristics of ataxin-3 isoforms.

Authors:  Daniel Weishäupl; Juliane Schneider; Barbara Peixoto Pinheiro; Corinna Ruess; Sandra Maria Dold; Felix von Zweydorf; Christian Johannes Gloeckner; Jana Schmidt; Olaf Riess; Thorsten Schmidt
Journal:  J Biol Chem       Date:  2018-11-19       Impact factor: 5.157

9.  Nucleocytoplasmic shuttling activity of ataxin-3.

Authors:  Sandra Macedo-Ribeiro; Luísa Cortes; Patrícia Maciel; Ana Luísa Carvalho
Journal:  PLoS One       Date:  2009-06-08       Impact factor: 3.240

10.  Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3.

Authors:  Fiona M Menzies; Jeannette Huebener; Maurizio Renna; Michael Bonin; Olaf Riess; David C Rubinsztein
Journal:  Brain       Date:  2009-12-09       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.